Hydrocortisone for Severe CAP

Community Acquired Pneumonia (CAP) has a high mortality rate. A new study evaluates the use of hydrocortisone for severe CAP in the ICU setting. Join host, Geoff Wall, as he evaluates if the evidence stacks up. The GameChanger The use of steroids to treat severe pneumonia has waxed and waned for many years with insufficient evidence. A recent study found steroids improved a number of outcomes, including mortality. Show Segments 00:00 - Introductions 01:19 - Past Studies on CAP Treatment 03:32 - The CAPE Code Study 17:05 - The GameChanger: The Study Findings 24:31 - Connecting to Practice: Study Limitations 26:01 - Closing Remarks Host Geoff Wall, PharmD, BCPS, FCCP, BCGP Professor of Pharmacy Practice, Drake University Internal Medicine/Critical Care, UnityPoint Health References and Resources Hydrocortisone in Severe Community-Acquired Pneumonia Redeem your CPE here CPE (Pharmacist) Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode) Pharmacists: Get a membership CE Information Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Describe the past history of major mortality studies for CAP pharmacotherapy 2. Discuss the CAPE Code study and its possible implications in the ICU 0.05 CEU/0.5 Hr UAN: 0107-0000-23-147-H01-P Initial release date: 04/24/2023 Expiration date: 04/24/2024 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram